98%
921
2 minutes
20
In recent years, the growing prevalence of group activities has brought increased interest in Point of Interest (POI) recommendations for groups. While significant progress has been made in recommending POIs for fixed groups, research on personality-aware recommendations for random groups has been still largely untouched. Moreover, existing works recommend a POI list for a group and the group makes further choice of the optimal POI, which results in poor user experience. To solve the above problems, this work proposes a model for Accurate POI Recommendation for Random Groups with improved Graph Neural Networks and a Multi-negotiation Model (termed as APRRGM). Specifically, APRRGM first produces the fitted feature of the random group based on group members' personalities and their POI interaction data. Then, APRRGM learns POIs' features from the bipartite graph of user and POI with an improved Graph Neural Networks (GNN) while considering members' personalities. Next, APRRGM recommends a POI sequence based on the fitted feature of the random group and the features of POIs. Finally, based on the recommended POI list and members' personalities, APRRGM determines the optimal POI for the random group with an improved multi-negotiation model. The extensive experiments conducted on three public benchmark datasets (Yelp, Gowalla, and Foursquare) have proved that APRRGM performs better than other baseline models.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876690 | PMC |
http://dx.doi.org/10.1038/s41598-025-91805-3 | DOI Listing |
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFStroke
September 2025
Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University.
Background: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain.
Methods: CHANCE-2 (Clopidogrel in High-Risk Patients With Acute Non-disabling Cerebrovascular Events-II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles.
Eur J Case Rep Intern Med
July 2025
Servicio de Alergia e Inmunología, Hospital Británico de Buenos Aires, Argentina.
Introduction: Interstitial lung disease is a major complication in patients with common variable immunodeficiency. There are some publications that try to shed light on the pathophysiology of this non-infectious complication, most of them highlight the role of follicular T cells and CD21 B cells. Moreover, there are no guidelines based on randomized controlled studies on the treatment of patients with interstitial lung disease and the published case series or small uncontrolled studies describe a wide range of response rates to treatment.
View Article and Find Full Text PDFInt J Gen Med
September 2025
Department of Pediatric, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, 130000, People's Republic of China.
Background: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, current treatments are limited by resistance and side effects. This study aims to evaluate the clinical efficacy and safety of combining Qingke Mixture with azithromycin for treating MPP in children.
Methods: This prospective, randomized, double-blind, controlled trial included 92 children diagnosed with MPP.